Reporting from ESMO Virtual Congress 2020, Noemi Reguart comments on long term follow-up results from studies testing first-line and maintenance immunotherapy in advanced NSCLC. She also discusses promising results testing a combination of ICI with chemotherapy in extensive stage SCLC, and emphasises the need for more exploration to identify which groups of patient may benefit the most.
Abstracts:
- LBA12 - PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of palbociclib with adjuvant endocrine therapy versus adjuvant endocrine therapy alone for HR+/HER2- early breast cancer
- LBA5_PR - Abemaciclib for the adjuvant treatment of high-risk early breast cancer
Simultaneous publication: https://ascopubs.org/doi/full/10.1200/JCO.20.02514
This video was supported with educational grants from Bayer, Daiichi Sankyo and Novartis